Skip to content

Brain-body integromics of the ayahuasca experience.

Francisco Madrid-Gambin, Pablo Mallaroni, Noemí Haro, Oscar J Pozo, Natasha L Mason, Johannes T Reckweg, Lilian Kloft-Heller, Kim van Oorsouw, Stefan W Toennes, Johannes G Ramaekers

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie June 1, 2026 DOI: 10.1016/j.biopha.2026.119391 via PubMed

Summary

AI-generated from the abstract

The psychedelic state induced by ayahuasca arises from coordinated, system-level interactions between peripheral metabolism and brain network dynamics, rather than isolated neurochemical events. In 20 experienced ceremonial users, the subjective dimensions of oceanic boundlessness, visionary restructuralization, and auditory alterations covaried with circulating DMT and β-carbolines, shifts in lipid, amino acid, and energy metabolism, and reconfiguration of dorsal attention and default mode network connectivity. Shared features across these experiences were most strongly linked to endocannabinoid-related N-acylethanolamines, acylglycerols, and ceramides, extending beyond canonical serotonergic models to downstream lipid-signaling and metabolic processes. The findings offer translational insight into metabolic pathways that may modulate brain function and subjective response.

Study at a glance

Characteristics Within-subject, integrative multiblock partial least squares framework with complementary ¹H-MRS and rCCA analyses Peer reviewed
Sample size 20
Population Experienced ceremonial ayahuasca users
Intervention Ayahuasca
Topics Ayahuasca DMT
Keywords Connectome Integromics Metabolomics
Key finding Psychedelic states reflect coordinated, system-level interactions between peripheral metabolism and functional brain networks, with subjective experience dimensions linked to specific circulating alkaloids, metabolic alterations, and brain network reconfigurations.

Abstract

Ayahuasca is a psychoactive brew containing N,N-dimethyltryptamine (DMT) and β-carboline alkaloids that induces marked alterations in perception, emotion and self-referential processing. However, the multiscale biological organization linking peripheral metabolism, brain network dynamics, neurochemistry, and subjective experience in humans remains poorly understood. Here, we applied an integrative, within-subject, multiblock partial least squares framework to model coordinated changes across four complementary biological and phenotypic layers: plasma psychoactive alkaloids, targeted metabolomics, resting-state fMRI-derived functional connectomes, and multidimensional subjective experience assessed with the 5-Dimensional Altered States of Consciousness (5D-ASC) scale, in 20 experienced ceremonial ayahuasca users. Complementary ¹H-MRS data were used to examine associations between peripheral metabolism, posterior cingulate cortex neurochemistry, and default mode network (DMN)-related connectivity. Multilayer integration revealed that the experiential dimensions oceanic boundlessness, visionary restructuralization and auditory alterations covaried with circulating DMT and β-carbolines, alterations in lipid, amino acid and energy metabolisms and reconfiguration of dorsal attention- and DMN-related connectivity. Shared network features across experiential dimensions were most strongly associated with endocannabinoid-related N-acylethanolamines, acylglycerols, and ceramides, extending canonical serotonergic models toward downstream lipid-signalling and metabolic processes. Complementary rCCA analyses further showed structured covariation between peripheral metabolites, posterior cingulate cortex neurochemistry, and DMN-related connectivity. Together, these findings indicate that psychedelic states reflect coordinated, system-level interactions between peripheral metabolism and functional brain networks rather than isolated neurochemical or neural events. Framed within a brain-body integromics perspective, this work provides translationally relevant insight into metabolic pathways that may modulate brain function and subjective response, with potential implications for neuropsychiatric and pharmacometabolic research.

Explore topics

Comments

No comments yet.

Log in to comment